【Healthkoreanews】 Korea Green Cross is going to make a Phase 3 clinical trial for Peramivir -an experimental anti-viral drug for the treatment of influenza- from Dec. 2008 to June 2009.
The Phase 3 clinical trial, in which 1050 patients with influenza will be surveyed, is to be conducted in Korea, Japan, Taiwan and Hongkong by Korea Green Cross and Shionogi & Co..
Peramivir was made by BioCryst in U.S.A for the treatment of acute influenza, including infection caused by highly virulent, life-threatening strains of influenza.
BioCryst has strategic partnership with Korea Green Cross. They entered into an agreement to develop and commercialize Peramivir in South Korea in June, 2006.
An offical of Korea Green Cross said, "'GC501’, Korea's first influenza vaccine, will be rolled out at the end of 2009."
Korea Green Cross has aimed to build a defense system against influenza in Korea. <헬스코리아뉴스>